发布于: 雪球转发:0回复:3喜欢:0

$Exicure(XCUR)$   风险无处不在,现金流不充裕、研究推进缓慢,竟然还有前员工打官司

Exicure, Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 (the “Q3 2021 10-Q”) with the Securities and Exchange Commission (“SEC”) within the prescribed time period without unreasonable effort or expense. On November 9, 2021, the Audit Committee of the Board of Directors of the Company was notified of a claim made by a former Company senior researcher regarding alleged improprieties that researcher claims to have committed with respect to the Company’s XCUR-FXN preclinical program for the treatment of Friedreich’s ataxia. The Audit Committee has retained external counsel to conduct an internal investigation of the claim. The Company is currently unable to predict the timing or outcome of the investigation. Despite working diligently in an effort to timely file its Q3 2021 10-Q, the Company requires additional time to complete certain disclosures and procedures, including disclosures relating to the internal investigation.

全部讨论

2021-11-22 16:39

当天卖出,躲过一劫

2021-11-17 22:21

撤了,好的idea需要好的掌舵人才能变成现实

2021-11-16 13:06

Exicure, Inc.(以下简称“本公司”)无法在规定的时间内向美国证券交易委员会(以下简称“SEC”)提交截至2021年9月30日的季度报告(以下简称“2021年第三季度10-Q”)。2021年11月9日,公司董事会审计委员会收到公司一名前高级研究员提出的索赔,该研究员声称在公司治疗弗里德希氏共济失调的xcure - fxn临床前项目中存在不当行为。审计委员会已聘请外部顾问对索赔进行内部调查。该公司目前无法预测调查的时间或结果。尽管公司正在努力及时提交2021年第三季度10-Q报告,但公司需要额外的时间来完成某些披露和程序,包括与内部调查有关的披露。